Brief Report| Volume 44, ISSUE 8, P1161-1171, August 2022

Design and Protocol of the Renal Anhydramnios Fetal Therapy (RAFT) Trial



      Anhydramnios secondary to anuria before 22 weeks of gestational age and congenital bilateral renal agenesis before 26 weeks of gestational age are collectively referred to as early-pregnancy renal anhydramnios. Early-pregnancy renal anhydramnios occurs in at least 1 in 2000 pregnancies and is considered universally fatal when left untreated because of severe pulmonary hypoplasia precluding ex utero survival The Renal Anhydramnios Fetal Therapy (RAFT) trial is a nonrandomized, nonblinded, multicenter clinical trial designed to assess the efficacy, safety, and feasibility of amnioinfusions for patients with pregnancies complicated by early-pregnancy renal anhydramnios. The primary objective of this study is to determine the proportion of neonates surviving to successful dialysis, defined as use of a dialysis catheter for ≥14 days.


      A consortium of 9 North American Fetal Therapy Network (NAFTNet) centers was formed, and the RAFT protocol was refined in collaboration with the NAFTNet Scientific Committee. Enrollment in the trial began in April 2020. Participants may elect to receive amnioinfusions or to join the nonintervention observational expectant management group. Eligible pregnant women must be at least 18 years of age with a fetal diagnosis of isolated early-pregnancy renal anhydramnios.


      In addition to the primary study objective stated above, secondary objectives include (1) to assess maternal safety and feasibility of the serial amnioinfusion intervention (2) to perform an exploratory study of the natural history of untreated early pregnancy renal anhydramnios (3) to examine correlations between prenatal imaging and lung specific factors in amniotic fluid as predictive of the efficacy of serial percutaneous amnioinfusions and (4) to determine short- and long-term outcomes and quality of life in surviving neonates and families enrolled in RAFT


      The RAFT trial is the first clinical trial to investigate the efficacy, safety, and feasibility of amnioinfusions to treat the survival-limiting pulmonary hypoplasia associated with anhydramnios. Although the intervention offers an opportunity to treat a condition known to be almost universally fatal in affected neonates, the potential burdens associated with end-stage kidney disease from birth must be acknowledged. identifier: NCT03101891.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ruano R
        • Safdar A
        • Au J
        • Koh CJ
        • Gargollo P
        • Shamshirsaz AA
        • et al.
        Defining and predicting “intrauterine fetal renal failure” in congenital lower urinary tract obstruction.
        Pediatric Nephrology (Berlin, Germany). 2016; 31: 605-612
        • Dias T
        • Sairam S
        • Kumarasiri S.
        Ultrasound diagnosis of fetal renal abnormalities.
        Best Practice & Research Clinical Obstetrics & Gynaecology. 2014; 28: 403-415
        • Moxey-Mims M
        • Raju TNK.
        Anhydramnios in the setting of renal malformations: the National Institutes of Health Workshop Summary.
        Obstet Gynecol. 2018; 131: 1069-1079
        • Jelin AC
        • Sagaser KG
        • Forster KR
        • Ibekwe T
        • Norton ME
        • Jelin EB.
        Etiology and management of early pregnancy renal anhydramnios: is there a place for serial amnioinfusions?.
        Prenatal Diagnosis. 2020; 40: 528-537
        • O'Hare EM
        • Jelin AC
        • Miller JL
        • Ruano R
        • Atkinson MA
        • Baschat AA
        • et al.
        Amnioinfusions to treat early onset anhydramnios caused by renal anomalies: background and rationale for the renal anhydramnios fetal therapy trial.
        FDT. 2019; 45: 365-372
        • Polin RA
        • Fox WW
        • Abman SH.
        Fetal and Neonatal Physiology E_Book.
        Elsevier Health Sciences, 2011
        • Hooper SB
        • Polglase GR
        Roehr CC. Cardiopulmonary changes with aeration of the newborn lung.
        Paediatr Respir Rev. 2015; 16: 147-150
        • Kitterman JA.
        The effects of mechanical forces on fetal lung growth.
        Clin Perinatol. 1996; 23: 727-740
      1. Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial | Elsevier Enhanced Reader [Internet]. [cited 2020 Nov 20]. Available from:

        • Vinit N
        • Gueneuc A
        • Bessières B
        • Dreux S
        • Heidet L
        • Salomon R
        • et al.
        Fetal cystoscopy and vesicoamniotic shunting in lower urinary tract obstruction: long-term outcome and current technical limitations.
        FDT. 2020; 47: 74-83
        • Bienstock JL
        • Birsner ML
        • Coleman F
        • Hueppchen NA
        Successful in utero intervention for bilateral renal agenesis.
        Obstet Gynecol. 2014; 124: 413-415
        • Whittaker N
        • Leonardi M.
        Five-month survival of neonate after serial amnioinfusions for fetal bilateral renal agenesis [18D].
        Obstet Gynecol. 2016; 127: 39S
        • Haeri S
        • Simon DH
        • Pillutla K.
        Serial amnioinfusions for fetal pulmonary palliation in fetuses with renal failure.
        J Matern Fetal Neonat Med. 2017; 30: 174-176
        • Mauer SM
        • Dobrin RS
        • Vernier RL.
        Unilateral and bilateral renal agenesis in monoamniotic twins.
        J Pediatr. 1974; 84: 236-238
        • Perez-Brayfield MR
        • Kirsch AJ
        • Smith EA
        Monoamniotic twin discordant for bilateral renal agenesis with normal pulmonary function.
        Urology. 2004; 64: 589
        • Klinger G
        • Merlob P
        • Aloni D
        • Maayan A
        • Sirota L.
        Normal pulmonary function in a monoamniotic twin discordant for bilateral renal agenesis: report and review.
        Am J Med Genet. 1997; 73: 76-79
        • Cilento BG
        • Benacerraf BR
        • Mandell J.
        Prenatal and postnatal findings in monochorionic, monoamniotic twins discordant for bilateral renal agenesis-dysgenesis (perinatal lethal renal disease).
        J Urol. 1994; 151: 1034-1035
      2. Congresswoman's “Miracle Baby” Gets a Kidney – from her Dad! | [Internet]. [cited 2020 Oct 15]. Available from:

      3. Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies - Abstract - Fetal Diagnosis and Therapy 2017, Vol. 41, No. 1 - Karger Publishers [Internet]. [cited 2020 Nov 17]. Available from:

        • Riddle S
        • Habli M
        • Tabbah S
        • Lim FY
        • Minges M
        • Kingma P
        • et al.
        Contemporary outcomes of patients with isolated bilateral renal agenesis with and without fetal intervention.
        Fetal Diagn Ther. 2020; 47: 675-681
        • Jelin EB
        • Atkinson M
        • Keiser A
        • Blumenfeld YJ
        • Baschat AA.
        Response to “Contemporary Outcomes of Patients with Isolated Bilateral Renal Agenesis with and without Fetal Intervention” by RAFT Investigators.
        FDT. 2020; 47: 785-786
        • Sugarman J
        • Anderson J
        • Baschat AA
        • Herrera Beutler J
        • Bienstock JL
        • Bunchman TE
        • et al.
        Ethical considerations concerning amnioinfusions for treating fetal bilateral renal agenesis.
        Obstet Gynecol. 2018; 131: 130-134
        • Maturana A
        • Bernard A
        • Germain AM
        • Chau VL
        • Moya FR.
        Amniotic fluid clara cell protein concentration in normal pregnancy, a marker of fetal airway growth or fetal lung maturation?.
        J Perinatol. 2001; 21: 516-520
        • Torday JS
        • Rehan VK.
        Testing for fetal lung maturation: a biochemical “window” to the developing fetus.
        Clin Lab Med. 2003; 23: 361-383
      4. Biochemical development of the lung: clinical aspects of surfactant development, RDS and the intrauterine assessment of lung maturity. - Abstract - Europe PMC [Internet]. [cited 2020 Nov 20]. Available from:

        • Thomas AN
        • McCullough LB
        • Chervenak FA
        • Placencia FX.
        Evidence-based, ethically justified counseling for fetal bilateral renal agenesis.
        J Perinat Med. 2017; 45: 585-594
        • Alfirevic Z
        • Navaratnam K
        • Mujezinovic F.
        Amniocentesis and chorionic villus sampling for prenatal diagnosis.
        Cochrane Database Syst Rev. 2017 Sep 4; 2017 ([Internet][cited 2020 Nov 20]Available from:)